Docmorris Ltd · SIX:DOCM
Docmorris — H1 2021 Earnings Presentation
21 slides from Docmorris's earnings presentation, Aug 18, 2021
Slide 1: Zur Rose Group
ZurRose Group
Slide 2: H1 2021 Results Conference Call
H1 2021 Results Conference Call
Slide 3: Today's presenters
Today’s presenters Walter Oberhansli Founder, Group CEO Zur Rose Group Marcel Ziwica Group CFO Hi 2021 Results Walter Hess Head Germany
Slide 4: Introduction: H1 2021 in review
Introduction H1 2021 in review Revenue growth accelerates to Number of active customers reaches 26.2% in Q2 11.7 million Significant Hi revenue Madhu Nutakki First flight of DocMorris wins Germany 30.0% announced as CTO DocMorris marketing 8 brand awards Switzerland 5.6% of Zur Rose Group campaign i
Slide 5: Introduction: key messages
Introduction 1. «Once in a lifetime» eRx opportunity 2. Customer centricity is at our core 3. Creating Europe’s leading Healthcare Ecosystem 4. Leverage existing platforms and resources to become the tech leader 5. Management committed to execute and create value
Slide 6: Financial Update
Financial Update
Slide 7: Zur Rose Group Sales H1 2021
Zur Rose Group Sales in million CHF +20.8%1 +22.9%1 +30.0%1 +5.6% 998.02 809.9 H1 2020 Switzerland Germany Europe H1 2021 external revenue(3) external revenue(3) external revenue(3) Notes: 1 In local currencies | 2 Including eliminations of CHF 3.6 million | 3 Consolidated revenue of the Zur Rose Gr
Slide 8: Zur Rose Group Sales Q2 2021
Zur Rose Group Sales in million CHF +26.2%1 +35.6%1 +1.2%1 +14.9% 495.32 383.4 Q2 2020 Switzerland Germany Europe Q2 2021 external revenue3 external revenue3 external revenue3 Notes: 1 in local currencies | 2 Including eliminations of CHF 2.2 million | 3 Consolidated revenue of the Zur Rose Group in
Slide 9: Group B2C & Marketplace KPIs
Group B2C & Marketplace KPIs Active customers1 Repeat order rate2 Site visits3 in millions +12.9% +11.4% H1 2020 FY 2020 H1 2021 H1 2020 FY 2020 H1 2021 Basket size4 Order frequency5 in EUR 1.1 (1.3%) (2.2%) 11.7 10.5 (2.2%) (5.1%) 8.1 54 54 52 2.4 2.2 2.2 H1 2020 FY 2020 H1 2021 H1 2020 FY 2020 H1
Slide 10: Income Statement H1 2021
Zur Rose Group Income Statement H1 2021 Margin in % H1 2020 Margin in % in million CHF External revenue 998.0 809.9 Consolidated revenue 839.8 698.0 Gross profit adj. 136.9 16.3 121.4 17.4 Personnel expenses adj. (73.2) (8.7) (60.9) (8.7) Marketing expenses (49.4) (5.9) (27.6) (4.0) Distribution exp
Slide 11: Income Statement: EBITDA adjustments
Zur Rose Group Income Statement H1 2020 H1 2021 EBITDA adjustments Adj. EBITDA adjustments Adj. EBITDA EBITDA in million CHF in million CHF (3.5%) (1.6%) (5.9%) (5.1%) Integration M&A (11.5) 2.1 (24.5) 10.9 M&A Integration Other2 1.2 0.7 (42.9) (49.7) 5.0 Notes: 1 Founders of acquired businesses | 2
Slide 12: Income Statement: Adj. EBITDA bridge
Zur Rose Group Income Statement H1 2020 H1 2021 Adj. Adj. EBITDA EBITDA in million CHF (1.6%) (5.1%) eRx (11.5) New businesses 14.2 Gross margin 6.0 other 9.2 2.0 (42.9)
Slide 13: Balance Sheet
Zur Rose Group Balance Sheet 30 June 2021 % 31 Dec 2020 % in million CHF Cash and cash equivalents 251.7 300.6 Receivables 161.1 145.4 Inventories 83.9 92.9 Property, plant & equipment 99.1 96.6 Intangible assets 617.0 604.5 Other assets 38.6 38.5 Total assets 1251.4 1278.5 Financial liabilities 87.
Slide 14: Financial Outlook
Financial Outlook
Slide 15: Financial Outlook: Group Outlook 2021
Financial Outlook Group Outlook 2021: Continued strong sales growth and marketing push ahead of eRx introduction external revenue growth of around 20% Break-even on EBITDA is targeted within 12-18 months after 2021 Hi 2021 Results
Slide 16: Financial Outlook: Mid-term targets
Financial Outlook Mid-term targets: Huge potential of increasing online penetration of Rx and EBITDA margin of 8% The implementation of the healthcare eco-system is creating meaningful potential for additional revenue and profit upside Zur Rose Group H1 2021 Results
Slide 17: Financial Outlook: run-rate to mid-term EBITDA margin
Financial Outlook 17% (4%) 2020 (12%) (3%) 2% 0% Sales Gross margin Variable costs (1) Variable costs (1) Other expenses Growth Adj. EBITDA initiatives before expenses in Increasing OTC growth initiatives margin Lower picking Higher marketing Organisational costs efficiency synergies Run-rate 2-3% S
Slide 18: eRx Update
eRx Update ‘Zur Rose Group Hi 2021 Results 18
Slide 19: eRx Update: test phase and rollout timeline
eRx Update Test phase in focus region Berlin Brandenburg to evaluate application Q3 2021 Nationwide introduction to increase availability and acceptance Q4 2021 Mandatory introduction for all stakeholders 1 January 2022
Slide 20: eRx Update: example screenshot
eRx Update Note: Example screenshot for illustration purposes
Slide 21: Q&A
Q&A ‘Zur Rose Group Hi 2021 Results 21